301201 誠達藥業
按盤價 
49.200 +8.200 (+20.000%)
49.200 +8.200 (+20.000%) | 2025/09 - 九個月 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | 0.785 | -1.272 | 4.051 | 7.762 | 20.345 |
| 總資產報酬率 ROA (%) | 0.698 | -1.149 | 3.809 | 7.087 | 16.500 |
| 投入資產回報率 ROIC (%) | 0.752 | -1.229 | 4.004 | 7.529 | 18.666 | 邊際利潤分析 |
| 銷售毛利率 (%) | 45.391 | 42.821 | 42.886 | 48.009 | 49.972 |
| 營業利潤率 (%) | 6.682 | -7.375 | 26.019 | 30.196 | 28.250 |
| 息稅前利潤/營業總收入 (%) | 6.341 | -9.372 | 23.299 | 27.876 | 28.389 |
| 淨利潤/營業總收入 (%) | 5.890 | -8.297 | 21.989 | 25.878 | 24.120 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 43.891 | 220.512 | 60.248 | 71.297 | 97.058 |
| 價值變動淨收益/利潤總額(%) | 71.377 | -119.156 | 40.119 | 33.021 | 0.000 |
| 營業外收支淨額/利潤總額(%) | -5.984 | 9.614 | -3.404 | -3.445 | -1.871 | 償債能力分析 |
| 流動比率 (X) | 7.383 | 6.844 | 9.578 | 16.876 | 1.529 |
| 速動比率 (X) | 6.505 | 6.190 | 8.817 | 15.305 | 0.824 |
| 資產負債率 (%) | 9.980 | 11.934 | 7.185 | 4.557 | 22.438 |
| 帶息債務/全部投入資本 (%) | 3.601 | 4.608 | 1.732 | 0.077 | 11.773 |
| 股東權益/帶息債務 (%) | 2,673.861 | 2,066.177 | 5,660.638 | 129,661.467 | 741.648 |
| 股東權益/負債合計 (%) | 900.886 | 737.035 | 1,290.864 | 2,092.776 | 345.234 |
| 利息保障倍數 (X) | 172.262 | 7.730 | -12.503 | -21.210 | 43.167 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 94.698 | 118.494 | 100.940 | 86.132 | 65.545 |
| 存貨周轉天數 (天) | 250.910 | 251.118 | 218.244 | 219.281 | 140.335 |
| 備註： | 報價延遲最少15分鐘，資料更新時間為 14/11/2025 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
